7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 7 of 7 clinical reviews.
A clinical review of resmetirom (Rezdiffra) efficacy and pharmacogenomic differences in East Asian patients, covering MAESTRO-NASH subgroup data, CYP2C19/CYP2D6 allele frequencies, BMI thresholds, and dosing considerations.
A clinician-focused guide to resmetirom dosing in Hispanic and Latino patients, covering MAESTRO-NASH subgroup data, CYP2C8 pharmacogenomics, NASH disease burden, and when a 60 mg vs. 100 mg starting dose is appropriate.
A detailed clinical review of resmetirom (Rezdiffra) efficacy data stratified by Black / African ancestry, including MAESTRO-NASH subgroup analysis, pharmacogenomic considerations, and dosing guidance for this population.
What the FDA label and trial evidence do, and do not, say about resmetirom dosing by race, ancestry, and pharmacogenomic testing.
Evidence-based review of resmetirom (Rezdiffra) efficacy in Hispanic and Latino populations, including MAESTRO-NASH subgroup data, CYP enzyme variants, and clinical dosing considerations for MASH treatment.
Evidence review of resmetirom (Rezdiffra) efficacy in South Asian populations, covering MAESTRO-NASH subgroup data, pharmacogenomic variability, THR-β agonism, MASH prevalence disparities, and adjusted dosing considerations.
A clinician-focused review of resmetirom pharmacogenomics, dosing considerations, and safety signals in South Asian patients with NASH/MASH, including ethnicity-stratified data from MAESTRO-NASH and population pharmacokinetic evidence.